TJH is on the MCBS working group for the European Society for Medical Oncology. Q-DT reports grants from Pfizer and consulting fees from Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, and ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

NEW YORK, Sept. 20, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

according to data presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, and published concomitantly in the Journal of Clinical Oncology. Patients ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...